Advertisement
U.S. markets closed

Exact Sciences Corporation (EXAS)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
62.74+1.77 (+2.90%)
At close: 04:00PM EST
63.40 +0.66 (+1.05%)
After hours: 07:50PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Slow Stochastic

Slow Stochastic

Previous Close60.97
Open60.01
Bid61.31 x 1200
Ask62.72 x 1100
Day's Range59.51 - 62.78
52 Week Range58.37 - 100.77
Volume2,132,786
Avg. Volume1,714,221
Market Cap11.347B
Beta (5Y Monthly)1.27
PE Ratio (TTM)N/A
EPS (TTM)-1.58
Earnings DateFeb 21, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est91.56
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for EXAS

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Exact Sciences Corporation
    Analyst Report: Exact Sciences CorporationExact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening, too.
    Rating
    Fair Value
    Economic Moat
    7 days agoMorningstar
View more